China's Hengrui and ChemPartner link up to develop novel antibodies
This article was originally published in Scrip
Executive Summary
In the first partnership of its type in China, a major pharma company in the country has joined forces with a domestic contract R&D organisation to develop and commercialise novel therapeutic monoclonal antibodies.